Jan 092018
 
Uniting to Combat Neglected Tropical Diseases (NTDs)

Uniting to Combat Neglected Tropical Diseases (NTDs) released their fifth progress report on the London Declaration on NTDs. The report describes the progress made toward achieving the goals set out by the London Declaration toward the control, elimination, and eradication of 10 NTDs. DOLF research on a more effective triple drug combination for lymphatic filariasis (LF) was highlighted as an important innovation that “can dramatically improve treatment for LF and decrease the duration of programmes.”   The report also celebrates Merck’s announcement to expand their donation in support of new triple-drug treatment.

  •  January 9, 2018
Nov 302017
 

Today Merck announced an expansion of the Mectizan Donation Program (MDP) to reach up to an additional 100 million people per year through 2025 to support the expansion of triple-drug therapy as part of the global effort to eliminate lymphatic filariasis (LF). DOLF research showed that adding ivermectin to diethylcarbamazine and albendazole can accelerate the time to reach LF elimination. WHO recently published new guidelines that recommend the triple drug combination for mass drug administration programs in settings where diethylcarbamazine and albendazole are already being used. These guidelines prompted Merck to expand its donation of Mectizan to countries outside of […]

  •  November 30, 2017
Oct 102017
 

Earlier today WHO published new guidelines for alternative MDA regimens for LF in the Weekly Epidemiological Record. The new guidelines recommend: • Triple drug therapy (IDA) for use in countries using diethylcarbamazine + albendazole (DA) in special settings • Annual ivermectin + albendazole (IA) rather than biannual IA in countries endemic for LF and onchocerciasis, except in areas already distributing biannual ivermectin for onchocerciasis • Biannual albendazole rather than annual ablendazole in implementation units where LF is coendemic with loiasis and ivermectin has not already been distributed DOLF studies provided important evidence to support these guidelines. The guidelines are tangible […]

  •  October 10, 2017
Sep 222017
 
DOLF Scientists Test New Scanner for Measuring Leg Swelling due to Filariasis

In March of 2017, DOLF researchers, Ramakrishna Rao and Philip Budge traveled to Galle, Sri Lanka to test a new portable scanner with the potential to revolutionize the measurement of limbs affected by lymphatic filariasis (LF). The scanner, which is produced by the Atlanta-based startup, LymphaTech, uses infrared scanning technology similar to that found in Microsoft’s X-Box Kinect, to create highly accurate virtual 3D reconstructions of solid objects. After meeting the scanner’s creators at national meeting in the fall, Doctors Budge and Rao wanted to see if this simple, portable scanner, which consists of an infrared sensor mounted on an […]

  •  September 22, 2017
Translate »